Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We.

Business Wire • Feb 4, 2026

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.

GlobeNewsWire • Jan 31, 2026

Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think

Travere Therapeutics (TVTX) is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-approved therapies for this disease.

Seeking Alpha • Jan 29, 2026

TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C.

PRNewsWire • Jan 28, 2026

TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

GlobeNewsWire • Jan 27, 2026

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?

Palisades added 137,768 shares of Travere Therapeutics; estimated trade size $5.26 million based on quarterly average price. The position represents 1.99% of 13F assets under management (AUM).

The Motley Fool • Jan 25, 2026

Top 3 Health Care Stocks That Could Blast Off This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Jan 21, 2026

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #TVTX--Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements to investors.

Business Wire • Jan 16, 2026

Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses

Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have lost money in their Travere Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.

Newsfile Corp • Jan 16, 2026

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX) complied with federal securities laws. On January 13, 2026, Travere disclosed that the U.S. Food and Drug Administration has extended the review timeline of its supplemental New Drug Application for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis. Following this news, the price of the Company's stock dropped.

GlobeNewsWire • Jan 14, 2026